Literature DB >> 25083255

Is tenofovir/emtricitabine teratogenic?

Murtala Jibril1, Oluwaseun Egunsola2.   

Abstract

The Truvada(®) (tenofovir/emtricitabine) and nevirapine combination is increasingly being prescribed for prevention of mother-to-child HIV transmission. There is presently no documented evidence of teratogenicity of either tenofovir/emtricitabine or nevirapine. We report two cases of spina bifida in infants of mothers on this drug combination.

Entities:  

Keywords:  emtricitabine; nevirapine; pregnancy; spina bifida; tenofovir; teratogenicity

Year:  2013        PMID： 25083255      PMCID： PMC4110866          DOI： 10.1177/2042098613485276

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


  7 in total

1.  Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?

Authors:  Louise Kuhn; Marc Bulterys
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

Review 2.  Etiology, pathogenesis and prevention of neural tube defects.

Authors:  Rengasamy Padmanabhan
Journal:  Congenit Anom (Kyoto)       Date:  2006-06       Impact factor: 1.409

3.  Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group.

Authors: 
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

4.  Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.

Authors:  Didier K Ekouevi; Patrick A Coffie; Eric Ouattara; Raoul Moh; Clarisse Amani-Bosse; Eugene Messou; Marcel Sissoko; Xavier Anglaret; Serge P Eholié; Christine Danel; François Dabis
Journal:  J Acquir Immune Defic Syndr       Date:  2011-02-01       Impact factor: 3.731

5.  Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects.

Authors:  P N Kirke; A M Molloy; L E Daly; H Burke; D G Weir; J M Scott
Journal:  Q J Med       Date:  1993-11

6.  Reproductive toxicology profile of emtricitabine in mice and rabbits.

Authors:  George M Szczech; Laurene H Wang; John P Walsh; Franck S Rousseau
Journal:  Reprod Toxicol       Date:  2003 Jan-Feb       Impact factor: 3.143

7.  Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.

Authors:  Diana M Gibb; Hilda Kizito; Elizabeth C Russell; Ennie Chidziva; Eva Zalwango; Ruth Nalumenya; Moira Spyer; Dinah Tumukunde; Kusum Nathoo; Paula Munderi; Hope Kyomugisha; James Hakim; Heiner Grosskurth; Charles F Gilks; A Sarah Walker; Phillipa Musoke
Journal:  PLoS Med       Date:  2012-05-15       Impact factor: 11.069
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.